Loading

Cialis Black

By S. Ines.

In the past cialis black 800 mg overnight delivery erectile dysfunction wellbutrin xl, various serendipitous discoveries have capitalized on the differential expression of enzymes by host and viral infected cells buy cialis black on line erectile dysfunction treatment kerala. These compounds are selectively phosphorylated intracellularly to the 5′-triphosphate derivatives which inhibit the viral reverse transcriptase. Drug delivery and targeting is a key area which will benefit from cell and tissue-based information. It seems reasonable to expect similarly sophisticated drug delivery end-points to be achievable through design or screening approaches, given an understanding of the tissue-specific expression of particular activating enzymes, possibly mirroring those already exploited by naturally occurring viruses. The storage of genomic and protein sequences in easily searchable databases to allow comparison of protein and genomic sequences is essential if companies are to maximize the value of their biological data. There are now a number of high quality protein and genetic databases documenting the protein and gene expression of specific cell types under different conditions. Such databases have proved invaluable to companies investigating specific disease states. With the increasing automation of drug discovery with respect to combinatorial chemistry, high- throughput screening, proteomics and genomics, informatics has developed an increasingly important role. The integration of robotics and informatics with databases correlating molecular properties with biological properties is becoming increasingly important for the management of compound libraries. Such informatic systems allow companies to readily search compound libraries and identify agents with potential activity against other therapeutic targets. Robotic automation provides a means of extracting these libraries or further screening from storage as necessary. The combination of biological and chemical data in relational databases provides useful data for the computer-based database searching and advanced quantitative structure-activity-relationship studies. The power of these databases in identifying potential lead compounds against new disease states will increase with the integration of proteomic data. For example, knowing that a specific compound class interacts strongly with a particular peptide motif at various receptors/catalytic sites will facilitate the identification of lead compounds for receptors/enzymes with similar motifs. Generic approaches towards the identification of new targets for human drug discovery are now routinely practised within pharmaceutical companies. Simply trawling these databases for potential targets expressed in diseased tissue has already yielded novel homologs of key enzymes and receptors, many of which have been patented as drug discovery targets. We are still at an early stage of understanding the full complexity of the mammalian and human genetic vocabulary. A more pharmaceutically oriented approach is to search for novel members of certain key receptor families which are already known from pharmacological studies to be present in a target tissue. This combination of pharmacology and molecular biology is proving particularly interesting, identifying far greater heterogeneity amongst targets than had previously been thought, with both receptor subtypes and the differential splicing of individual genes contributing to this complexity. The effective management of chemical and biological data underpins the effectiveness of any drug discovery group. All these aspects of drug discovery will impinge on drug delivery and targeting in the future. Furthermore, combinatorial chemistry and high-throughput screening will provide targeting molecules for disease-associated surface-expressed receptors and ligands. These may be linked to therapeutic drug molecules to increase epithelial transport by active transport processes and drug targeting selectivity. Describe the potential roles of proteomics and genomics in drug delivery and targeting. Identify two ways in which combinatorial chemistry may impinge on drug delivery and targeting. The preceding chapters in the last part of this book have highlighted the recent developments in gene therapy, drug discovery, genomics and proteomics as a consequence of the recent developments in molecular biology and chemistry. This chapter concludes this text by examining how the advances in chemistry and biology are providing opportunities for more effective site-specific drug targeting and bioresponsive pulsatile drug delivery. The chapter considers the development of prodrug-based technologies for cell-specific drug delivery, provides an overview of the use of smart polymeric systems, microchips and genetically engineered cell-based implants in addressing the challenges of chronopharmacology, and offers a perspective of the future of drug delivery and targeting in this new millennium. In the discovery process opportunities exist, as illustrated in Chapter 15, to identify cell-specific enzymes and ligands which may be used to target drugs to these cells. The integration of the considerations for drug delivery and targeting into the drug design process may ultimately allow the development of drugs which are not just potent and non-toxic but offer the advantage that their chemical structure dictates the targeting of the drug to its particular site of action through enzyme-based chemical delivery systems using prodrugs. A prodrug is a pharmacacologically inactive compound which undergoes chemical or enzymatic metabolism to the active. Some of the early pharmaceuticals were found to be prodrugs and this finding has led to the subsequent introduction of the metabolite itself into therapy, particularly in cases where the active metabolite is less toxic or has fewer side-effects than the parent prodrug. The administration of the active metabolite may also reduce variability in clinical response between individuals due to differences in pharmacogenetics. Most chemically designed prodrugs consist of two components; the active drug chemically linked to a pharmacologically inert moiety. The prodrug must be sufficiently stable to withstand the pharmaceutical formulation while permitting chemical or enzymatic cleavage at the appropriate time or site. After administration or absorption of the prodrug, the active drug is usually released by either chemical or enzymatic, hydrolytic or reductive processes. Prodrugs are most commonly used to overcome the biological and pharmaceutical barriers which separate the site of administration of the drug from the site of action (Figure 16. Prodrug design has been used to address a wide range of pharmaceutical problems including: • unpalatability • gastric irritation • pain on injection • insolubility • instability. Prodrug design has also been used widely to address pharmacological problems such as poor drug adsorption and drug distribution. As discussed in Chapter 1, prodrugs may be used to enhance the absorption of poorly adsorbed drugs by increasing the lipophilicity of the drug molecule. The modification of a drug to a prodrug may also lead to enhanced efficacy by differential distribution of the prodrug to particular body tissues before the release of the active drug. For example, the administration of the methoxymethyl ester of hetacillin (a 6-side-chain derivative of ampicillin) leads to a more extensive distribution of ampicillin in the body tissues than occurs on administration of ampicillin itself. Conversely, the restriction of tissue distribution which decreases toxic side-effects by restricting the action of a drug to a specific target site in the body may also be achieved through the use of certain prodrug systems as described below. An alternative strategy is to utilize phenotypic differences between cell types to target prodrugs to particular sites within the body through site- specific enzyme-based delivery systems. Improved selective localization of anticancer agents to neoplastic tissue may be achieved using non-toxic prodrugs which release the active drug within the tumor as a result of enhanced enzyme activity in the cell. For example, the prodrug cyclophosphamide is initially activated by hepatic cell enzymes to generate 4- hydroxycyclophosphamide which is then specifically converted to the alkylating cytotoxic phosphoramide mustard in the target cells. As the blood supply to large solid tumors is disorganized, the internal regions are often non-vasculated and the cells, termed hypoxic, deprived of oxygen. The absence of molecular oxygen enhances the reductase activity in hypoxic tissues providing an alternative means of targeting the internal regions of solid tumors using a selective chemical prodrug-delivery system. Certain aromatic, heterocyclic nitro-containing compounds can be reduced in hypoxic environments to produce intermediates which then fragment into alkylating species. For example, the 2-nitro-imidazole compound misonidazole is selectively cytotoxic to cultured hypoxic cells.

View Online The Challenges of Conducting Clinical Trials in Diseases with Small Target Populations 77 33 buy cialis black 800mg low cost erectile dysfunction causes premature ejaculation. Turner and American Heart Association Statistics Committee and Stroke Statistics Subcommittee discount 800mg cialis black fast delivery erectile dysfunction doctor el paso, Circulation, 2012, 125,e2–e220. Kang, View Online The Challenges of Conducting Clinical Trials in Diseases with Small Target Populations 79 E. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Registration of Pharmaceuticals for Human Use, Choice of control group and related issues in clinical trials E10, http://www. View Online Treating Rare Diseases: Business Model for Orphan Drug Development 85 Table 4. Each period outlines tremendous growth in output to a peak at the end of the period. In addition, the second and third periods are characterised by a nadir at the beginning, resulting from a fall-off in output from the preceding period’s peak due to macro-level market factors, aer which the growth uptick restarts. This paradigm and associated trends, conrmed based on updates with more recent output data, are illustrated in Table 4. Key points to highlight from this three-stage distribution of orphan drug development market output include the importance of market shocks resulting from a fall-off in output from the previous peak (i. Indeed, among therapeutic areas, oncology represents a majority share of new orphan disease therapies that come to market (i. Current estimates indicate that there are 5000–8000 rare diseases in the world for which Orphanet, a European organisation, has done systematic identication and classication. Many orphan diseases are characterised by a tight-knit community of patients, care-givers and treating healthcare professionals, which shares information among members on symptoms, disease characteristics, treatment options and new therapies being investigated, including potential clinical trials to participate in. Quite oen, these communities are built on the backbone of formal organisations (i. The degree of community ‘stickiness’ for many orphan diseases will inuence many of the key factors that underpin overall product development approaches for new orphan drugs. Orphan drugs, with current global revenues of $83 billion, have become an increasingly large and important part of the global pharmaceutical market, for which global sales in 2012 amounted to $645 billion. View Online Treating Rare Diseases: Business Model for Orphan Drug Development 89 Figure 4. View Online 90 Chapter 4 The following sections will explore orphan drug product development, commercialisation, investment and economics, as well as the future outlook for this rapidly developing and exciting sector within the biopharmaceutical industry. Second, orphan drug clinical programme strategy and execution is further challenged by uncertainties in the selection and characterisation of appropriate trial end points and treatment durations, paucity of robust biomarkers, recruiting the right patient populations and identifying qualied investigators. Special attention must be paid to ensure that the small patient populations for orphan diseases are characterised appro- priately, given biological and pharmacological heterogeneity/variability, as well as geographical distribution and scarcity. Additionally, for many orphan diseases, the lack of regulatory ‘precedent’ presents a challenge in itself. The scientic basis, level of evidence required, and context for biomarker use are areas to clarify. Accordingly, regulatory success oen requires robust and frequent inter- actions with regulatory agencies to gain alignment on key programme design elements including trial design, patient population requirements, clinical end points (e. The next few sections will discuss tradi- tional and emerging orphan drug product development platforms. A key example is bluebird bio, a gene therapy company focused on rare diseases, which uses its non-replicating lentiviral vector View Online 92 Chapter 4 Table 4. Monoclonal Immunoglobulins: based on Many Iniximab, antibodies specicity for antigenic rituximab epitopes 4. Gene therapy Vector-delivered gene sequences: 1 Alipogene replace decient/aberrant tiparvovec gene products 7. Pharmacological Small molecules: stabilize and/or 0 N/A chaperones reshape misfolded proteins aSmall molecules are low molecular weight (<900 Daltons) organic compounds and have been the main molecule platform for drug development. Large molecules (naturally occurring, recombinant, synthetic) comprise a broad cross-section of compound classes (e. LentiGlobin, which uses a similar vector but replaces beta-globin, is being evaluated for the treatment of beta thalassaemia major and sickle cell disease. Alipogene tiparvovec’s approval, based on clinical data from 27 patients, restricts prescribing to the subset of lipoprotein lipase deciency patients who have suffered repeated pancreatitis, and requires ongoing monitoring by the company, to demonstrate long-term efficacy and safety. There are a number of arguments for the proposed price: high pharmaceutical R&D costs in general, and alipogene tiparvovec’s high-cost development programme in particular (i. Interestingly, uniQure has proposed an ‘annuity’ approach to charging health systems for alipogene tiparvovec (e. Duchenne’s, an X-linked disease characterised by progressively debilitating natural history disease stages, has a spectrum of manifesta- tions with important implications for selecting clinical end points and trial design, on a background of a wide array of exon-deletion abnormal- ities. Thelattertwostages,affecting teenagers and older patients, exhibit more debilitating disease affecting cardiac, pulmonary and upper limb function. Prosensa’s exon-targeting therapeutic approach, which would create a ‘menu’ of therapies for each exon-deletion abnormality, is inuenced by the decreasing prevalence of the target exon (e. Based on this background, the clinical development and regulatory approach will probably pursue a full devel- opment programme for compounds addressing the most prevalent target exon mutations (e. Chaperones bring about therapeutic effect downstream of translation by ‘protecting’ their target proteins (e. Amicus Therapeutics, arguably the company with the broadest portfolio of small molecule pharmacological chaperones, is leveraging its technology platform to develop orally bioavailable therapies to address lysosomal storage disorders including Fabry, Gaucher and Pompe diseases. More so, orphan drug reim- bursement, by private or public payer, has traditionally been generous, affording most patients in the small orphan disease communities with access to medicines, which are oen life-saving and/or provide signicant quality of life attributes. Some of these payer management tools, approaches and tactics include the use of restrictive tiers, prior authorisation, step therapy, increased patient coinsurance and/or co-payment, genetic testing (i. Creative risk-sharing schemes, in addition to traditional patient access programmes and manufacturer discounts, are increasingly playing an important role in the provision of orphan drugs to patients. This concept is taken further with performance-based risk-sharing agreements for ultra-orphan therapies, where price reductions can be entertained or negoti- ated if clinical outcomes are suboptimal or not compelling, which provides an approach to address the uncertainty regarding the long-term effectiveness of costly ultra-orphan drugs. In summary, the key dimensions of commercialisation success around which companies must differentiate in order to win in the orphan drug market include understanding and exploiting orphan disease market fundamentals (e. There are two key evaluations or reports that have investigated this topic – the Drug Discovery Today article ‘Orphan Drug Development: An Economically Viable Strategy For Biopharma R&D’ (published in 2012), and EvaluatePharma’s ‘Orphan Drug Report’ (published in 2013). This indicates that mean per-year economic values of the orphan and non-orphan drug cohorts were almost equal, which underscores the value-creation viability of orphan drugs. View Online 102 Chapter 4 overall pharmaceutical market (excluding generics), as outlined in Figure 4. A separate analysis, in the same report, demonstrated a statistically signicant greater trend for multi-indication orphan drugs to target initial approval in an orphan vs. When the development plans for individual orphan drugs are being created, the cost, complexity, challenges and high-risk nature of pharmaceutical R&D in general should not be underestimated. The current trends in the orphan drug product development arena provide some interesting themes and an inno- vation imperative for inuencing the evolution of the biopharmaceutical landscape – for orphan drug R&D specically, as well as continual stimula- tion of biopharmaceutical R&D in general. Orphan drug R&D will make important contributions to life sciences research, drug discovery and translational medicine, thereby enhancing therapeutic development approaches (e. Indeed, orphan drug R&D experiences will help to advance the development and use of personalised/stratied medicine approaches and targeted medicines.

order cialis black uk

They have common properties: • a wide range of viscosity (400 to 15 order cialis black canada erectile dysfunction drugs available in india,000 cps); • compatibility with many topically applied drugs; • increased stability of the lacrimal film generic 800mg cialis black fast delivery drugs for erectile dysfunction ppt. Bioadhesives Bioadhesion is an interfacial phenomenon in which a synthetic or natural polymer becomes attached to a biological substrate by means of interfacial forces. If it involves mucin or mucous-covered membrane, the narrow term mucoadhesion is employed. Bioadhesion has been used to enhance bioavailability of drugs via various other routes including oral (Section 6. Bioadhesion may offer several unique features: 309 • localizing a dosage form within a particular region, increasing drug bioavailability; • promoting contact with the absorbing surface, permitting modification of tissue permeability in a restricted region; • prolonging residence time and reducing dosing frequency. The presence of mucin in the eye allows bioadhesive polymers to thicken the tear film in the front of eye. The hydrophilic groups on mucoadhesive polymers and the large amount of water associated with mucin present two possible adhesion mechanisms: (i) hydrogen bonding and (ii) interpenetration of a swollen gel network with hydrated mucin. Many methods have been used for the assessment of bioadhesive properties, including fluorescent techniques and tensile tests. By using these methods, a number of natural and synthetic polymers have been discovered possessing mucoadhesive properties. Natural polymers Sodium hyaluronate is a high molecular weight polymer extracted by a patented process from sources including chicken coxcombs. It consists of a linear, unbranched, non-sulphated, polyanionic glycosaminoglycan, composed of one repeating disaccharide unit of D-sodium glucuronate and N-acetyl-D- glucosamine. Products based on hyaluronates are widely used in intraocular surgery as a substitute for vitreous humor and as an adjuvant to promote tissue repair. Hyaluronates show a topical protective effect for the corneal endothelium and other delicate tissues from mechanical damage through providing a stabilized hydrogel. Sodium hyaluronate with its unusual rheological quality, producing a rapid transformation from a liquid to a solid character with increasing stress frequency, appears to be beneficial for topical vehicles. The pseudoplastic behavior of hyaluronate solutions, where viscosity is higher at the resting phase, provides a thickened tear film, slow drainage and an improved distribution on the cornea during blinking. Furthermore, the carboxyl groups of hyaluronate form hydrogen bonds with sugar hydroxyl groups of mucin when sodium hyaluronate is applied in the eye, producing an intimate contact with the cornea. These unique properties give hyaluronates great potential in ocular drug delivery. Chondroitin sulphate is another polysaccharide derivative (glycosaminoglycan) with a repeat unit containing β-D-glucoronic acid and D-N-acetyl galactosamine, very similar to hyaluronic acid except for modification of the position of a hydroxyl group and the addition of sulphate groups to the galactosamine residue. Chondroitin sulphate has a good affinity to the corneal surface, preventing premature breakup of the tear film between blinks. Formulations containing chondroitin have been used for the treatment of dry eye and showed superiority to hyaluronic acid in treating severe cases of keratoconjunctivitis sicca. Synthetic polymers Carbomers are poly (acrylic acid) polymers widely used in the pharmaceutical and cosmetic industries. They have several advantages, including high viscosities at low concentrations, strong adhesion to mucosa without irritation, thickening properties, compatibility with many active ingredients, good patient acceptability and low toxicity profiles. These properties have made carbomers very valuable in the field of ophthalmic formulations. Artificial tear products and novel drug delivery systems based on carbomers have been extensively formulated. A recent scintigraphic study on Geltears (a Carbopol 940 based product) showed that the precorneal residence is significantly prolonged by carbomer gel when compared to the saline control. Phase transition systems The introduction in the early 1980s of the concept of in situ gel systems demonstrated that a considerable prolongation in duration of action could be obtained. In situ gelling systems have unique properties, which can make a liquid change phase to a gel or solid phase in the culde-sac upon its instillation into the eye. Three methods have been employed to induce phase transition on the eye surface: change in pH and temperature as well as activation by ions. Cellulose acetate phthalate forms a pH-triggered phase transition system, which shows a very low viscosity up to pH 5. The half-life of residence on the rabbit corneal surface was approximately 400 seconds compared to 40 seconds for saline. However, such systems are characterized by a high polymer concentration, and the low pH of the instilled solution may cause discomfort to the patient. When the solution is instilled onto the eye surface (34 °C) the elevated temperature causes the solution to become a gel, thereby prolonging its contact with the ocular surface. One of the disadvantages of such a system is that it is characterized by a high polymer concentration (25% poloxamer), and the surfactant properties of poloxamer may be detrimental to ocular tolerability. Gellan gum is an anionic polysaccharide formulated in aqueous solution, which forms clear gels under the influence of an increase in ionic strength. The gellation increases proportionally to the amount of either monovalent or divalent cations. The reflex tearing, which often leads to a dilution of ophthalmic solutions, further enhances the viscosity of the gellan gum by increasing the tear volume and thus the increased cation concentration. It is also possible to develop systems which undergo both temperature and pH dependent changes in structure. Carbomers form acidic, low viscosity, aqueous dispersions that transform into stiff gels when the pH is raised. Although these aqueous materials can form gels in situ in the conjunctival sac upon instillation, they often cause irritation to the eye due to their high acidity and sometimes the dispersions are not easily neutralized by the buffering action of the tear fluid. Various polymer combinations have been investigated in attempts to improve the gelling properties and reduce the total polymer content of formulations, thereby improving their tolerability. Dispersed systems These can be grouped into suspensions, particulates, liposomes and emulsions. Suspensions 311 Suspensions are commonly formulated by dispersing micronized drug powder (< 10 μm in diameter) in a suitable aqueous vehicle. Ophthalmic suspensions, particularly for the steroids, are thought to be acceptable as delivery systems since it is assumed that drug particles persist in the conjunctival sac giving rise to a sustained release effect. However, suspensions have a disadvantage that the concentration of dissolved drugs cannot be manipulated due to their relative insolubility in the vehicle. Several investigators have shown the importance of particle size of the suspension in ocular drug delivery. Unfortunately, a particle size above 10 μm in diameter may result in a foreign body sensation in the eye following ocular application causing reflex tearing. A reduction in particle size generally improves the patient comfort and acceptability of suspension formulations. Particulates Although the suspension technique may be useful in extending drug release under certain conditions, it is only applicable to drugs that are practically insoluble in water, such as corticosteroids.

The decrease in the number of cells with age is an indicator of atrophic changes in the gastric mucosa over time order discount cialis black online erectile dysfunction gene therapy treatment. The data obtained suggest that the decrease in reparative and antioxidant effects of melatonin cialis black 800 mg amex impotence exercises, therefore, associated not only with physiological atrophy of the bone, and his extra pineal sources. A number of researchers suggest preferred macrophage response to corpuscular antigens as opposed to soluble ones. Furthermore, there is evidence that gold nanorods and nanorods coated with SiO2 penetrated into macrophages cause a release of inflammatory mediators (cytokines, prostaglandins) and activate immune response genes. Thus, further development of nanotechnologies requires a clear understanding of both the properties of nanomaterials and the mechanisms of their interaction with biological objects. Rare (orphan) diseases (the translation of this term from the Latin - "Orphan") affect a small group of the population. There is no Common international definition of orphan disease, as well as there is no common to all countries "rarity" criterion of disease. In Europe, it is considered a rare disease, when the disease occurs in 1 in 2,000 people. In Japan, the government acknowledged as carriers of rare diseases 50 thousand citizens. In Russia it is determined at the level of not more than 10 episodes per 100 thousand citizens. That is, the disease is considered an orphan drug if it occurs 1 in 10 000 people. According to statistics, 50% of patients with rare diseases - children; 10% of patients survive only up to five years; 12% - up to fifteen years; 50% of rare diseases lead to disability; every fifth patient suffers from pain; every third - can not lead an independent life. These diseases are not just a little expanded, but - chronic, severe or life-threatening illnesses, which may lead to disability, reduce life expectancy. Lamins A and C form a super twisted parallel dimers that polymerising form a fibrous network on nucleoplasmic side of the inner nuclear membrane. In the cells of patients with progeria nuclear shell shrivel, nucleus become irregularly 49 shaped. The main diagnostic feature of diseased cells is sharply reduced the number of divisions, which cells are able to pass in culture, the so-called limit or Hayflick number. As a result, the body does not just stop growing, but also loses its ability to replace dying cells with new, which leads to accelerated aging. The phenotype of patients is extremely characteristic: small stature, "bird person" with beak profile, the prevalence of brain the size of the skull on the front, alopecia. Observed defects in shape and number of teeth, dry, thinning skin, the almost complete absence of subcutaneous fat, developmental delays, especially physical. Negative processes are accompanied by the complications inherent to more elderly people: stroke, cardiovascular disease, osteoporosis, joint stiffness, generalized atherosclerosis. The cause of death is usually myocardial infarction with detection at autopsy generalized atherosclerosis and myocardial fibrosis, as well as concretion of lipoid in in the brain tissue and parenchyma organs. There is a wide range of pathology that accompanies normal aging: canities, alopecia, atherosclerosis, osteoporosis, cataracts, diabetes, cancer, geratic skin changes, infertility, impotence. Therefore, there is genetically determined instability of chromosomes, which is expressed in changing of the structure of chromosomes, that arise spontaneously or under the influence of some agents. Histological examination reveals atrophy of the epidermis and appendages of skin, dermis is thickened, collagen fibers are hyalinized, glucosamine contents is increased, the nerve fibers and blood vessels prone to degradation. Today, in the world it is recorded 42 cases of the disease progeria, in Ukraine - only 2. All methods of treatment used today, unfortunately, are not effective and pursued a single goal - to "freeze" the disease to the best of the possibilities of modern medicine. The minimal dose of aspirin is being used – in order to prevent heart attack, statins reduce cholesterol, anticoagulants inhibit the formation of clots, growth hormone increases height and weight, physiotherapy and exercises allow you to develop joints. Carboxytherapy is a method of treating diseases of different etiologies in the application of carbon dioxide. More than 30 years for the treatment and prevention of these diseases carboxytherapy used to eliminate inflammation, chronic articular and muscular pain. Until today, it was impossible to find a single universal method for the majority of diseases. According to pharmacological effects, the carbon dioxide can improve all the body systems, to improve the delivery of oxygen and nutrients, break down fats, eliminate toxins, regenerate tissue and contributing to the widening of capillary network. Also, carboxytherapy eliminate muscular and vascular spasms, relieves myofascial pain syndrome, eliminate venous stasis limfaticheskty that contributes to the improvement of health, improving health and quality of life. The topicality of this topic is that the traditional treatment of diseases associated with the musculoskeletal system, unfortunately, is not always effective. Carboxytherapy in combined administration with drugs widely used therapy at a pathology of the musculoskeletal system. Thus carboxytherapy through physiological mechanisms carbon action provides a number of therapeutic effects: antihypoxic, anti-inflammatory, antihypertensive, cardiotonic, metabolic, reparative and regenerative, antianginal, antispasmodic, analgesic, lipolytic and therefore primenenietsya not only in the treatment of pathologies of joints, but also in other diseases. Besides a high pharmacological activity, one of the most important requirements for medications is their safety. Ulcers of the gastric mucosa have been caused by the intragastric administration of 5 ml/kg of absolute alcohol to the animals fasted for 24 hours. To ensure effective treatment of burns the medicines of local action should identify antioxidant, anti-inflammatory, antimicrobial, reparative activity. But despite the wide range of other medicines on the pharmaceutical market of Ukraine actuality it`s the development of more effective treatments that extend the range of local medicines. Thermal burn is burn, which obtained by contact with a liquid, solid or gaseous heat source. The first place in the statistics occupy flame burns (about 84% of all thermal burns). Second-degree burns are superficial burns, since their depth is not sprout affects the skin layer, thus in places such skin burns itself is able to recover. The stabilization of membrane antioxidants in the 1st phase of wound healing ensures prevention of secondary necrosis, and in the 2nd is stimulate regeneration processes, so the purpose of the study was to investigate the intensity lipid and protein peroxidation in rats with burn wounds in the treatment of study medecines. Second-degree burn modeled in rats under tiopental anesthesia on the dehaired skin of back. To simulate second-degree burn using a special device with a metal plate with a diameter of 2. Blood sampling for analysis performed in two periods: the early discharge of crusts (7th days) and 21th days. In the experiment stick "General ethical animal experimentation" (Ukraine, 2001) harmonized with the "European Convention for the Protection of vertebrate animals used for experimental and other scientific purposes" (Strasbourg, 1985). In the treatment of animals studied gels observed activation of healing burn wounds.